Cipla Limited has inked a licensing agreement with a Belgium-based Multi G for the distribution of the latter’s Covid-19 Rapid Antibody test kit.
As per the licencing pact, Cipla will distribute the kit across most emerging markets and Europe. This is part of Cipla’s efforts to enhance global access to life-saving treatments and diagnostic infrastructure for patients in need.
Cipla said will be responsible for distribution of the Covid-19 rapid antibody kit that will be manufactured by MultiG and marketed under the brand name ‘Covi-G’.
According to Cipla, this was among the earliest Antibody kits to declare CE- compliance and is waiting for nod by ICH country regulators.
Over 20 countries
It has been commercialised in more than twenty countries already, with specificity and sensitivity exceeding 92 per cent. Using a single-prick blood test, it tests for both IgM and IgG antibodies. The kit gives results within 10 minutes.
Cipla’s expansive network, reach and partnerships with public health authorities as well as private institutions will aid in ensuring the seamless access of these kits across more than 25 markets in Asia, EU, Australia, Middle-East and North Africa and Latin America.
After ELIFAST diagnostic kits, this launch marks yet another addition to our COVID portfolio. Besides an epidemiological tool for mass screening, this point of care test can also be used to detect patients who have had a suspected asymptomatic or mild infection in the past, identify potential plasma donors and possibly prioritise susceptible people for vaccines.
(With inputs from The OnLook News Research Bureau)
If you like this article and if you feel it will be helpful for others to understand on the subject, please share it. You can also follow us on Twitter, Facebook & Linkedin
Also read: Biological E gets into war against Covid-19, commences clinical trial of its vaccine candidate